CLSD Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -740.66% compared to Clearside Biomedical's net margin of --. Clearside Biomedical's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Clearside Biomedical has a consensus price target of --, signalling upside risk potential of 516.78%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 357.51%. Given that Clearside Biomedical has higher upside potential than Perspective Therapeutics, analysts believe Clearside Biomedical is more attractive than Perspective Therapeutics.

Clearside Biomedical has a beta of 2.198, which suggesting that the stock is 119.786% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

Clearside Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearside Biomedical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Clearside Biomedical quarterly revenues are $1M, which are larger than Perspective Therapeutics quarterly revenues of --. Clearside Biomedical's net income of -$7.7M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Clearside Biomedical's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearside Biomedical is 8.90x versus 19.06x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Crinetics Pharmaceuticals has a net margin of -740.66% compared to Clearside Biomedical's net margin of -18560.15%. Clearside Biomedical's return on equity of -- beat Crinetics Pharmaceuticals's return on equity of -42.43%.

Clearside Biomedical has a consensus price target of --, signalling upside risk potential of 516.78%. On the other hand Crinetics Pharmaceuticals has an analysts' consensus of $73.38 which suggests that it could grow by 51.31%. Given that Clearside Biomedical has higher upside potential than Crinetics Pharmaceuticals, analysts believe Clearside Biomedical is more attractive than Crinetics Pharmaceuticals.

Clearside Biomedical has a beta of 2.198, which suggesting that the stock is 119.786% more volatile than S&P 500. In comparison Crinetics Pharmaceuticals has a beta of 0.596, suggesting its less volatile than the S&P 500 by 40.377%.

Clearside Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Crinetics Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearside Biomedical pays -- of its earnings as a dividend. Crinetics Pharmaceuticals pays out -- of its earnings as a dividend.

Clearside Biomedical quarterly revenues are $1M, which are larger than Crinetics Pharmaceuticals quarterly revenues of $399K. Clearside Biomedical's net income of -$7.7M is higher than Crinetics Pharmaceuticals's net income of -$76.8M. Notably, Clearside Biomedical's price-to-earnings ratio is -- while Crinetics Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearside Biomedical is 8.90x versus -- for Crinetics Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Corvus Pharmaceuticals has a net margin of -740.66% compared to Clearside Biomedical's net margin of --. Clearside Biomedical's return on equity of -- beat Corvus Pharmaceuticals's return on equity of --.

Clearside Biomedical has a consensus price target of --, signalling upside risk potential of 516.78%. On the other hand Corvus Pharmaceuticals has an analysts' consensus of $14.80 which suggests that it could grow by 161.95%. Given that Clearside Biomedical has higher upside potential than Corvus Pharmaceuticals, analysts believe Clearside Biomedical is more attractive than Corvus Pharmaceuticals.

Clearside Biomedical has a beta of 2.198, which suggesting that the stock is 119.786% more volatile than S&P 500. In comparison Corvus Pharmaceuticals has a beta of 1.073, suggesting its more volatile than the S&P 500 by 7.259%.

Clearside Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corvus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearside Biomedical pays -- of its earnings as a dividend. Corvus Pharmaceuticals pays out -- of its earnings as a dividend.

Clearside Biomedical quarterly revenues are $1M, which are larger than Corvus Pharmaceuticals quarterly revenues of --. Clearside Biomedical's net income of -$7.7M is higher than Corvus Pharmaceuticals's net income of -$40.2M. Notably, Clearside Biomedical's price-to-earnings ratio is -- while Corvus Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearside Biomedical is 8.90x versus -- for Corvus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -740.66% compared to Clearside Biomedical's net margin of --. Clearside Biomedical's return on equity of -- beat Viking Therapeutics's return on equity of --.

Clearside Biomedical has a consensus price target of --, signalling upside risk potential of 516.78%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 170.94%. Given that Clearside Biomedical has higher upside potential than Viking Therapeutics, analysts believe Clearside Biomedical is more attractive than Viking Therapeutics.

Clearside Biomedical has a beta of 2.198, which suggesting that the stock is 119.786% more volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.344%.

Clearside Biomedical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearside Biomedical pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Clearside Biomedical quarterly revenues are $1M, which are larger than Viking Therapeutics quarterly revenues of --. Clearside Biomedical's net income of -$7.7M is higher than Viking Therapeutics's net income of -$24.9M. Notably, Clearside Biomedical's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearside Biomedical is 8.90x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.